Zealand Pharma ASZLDPF 62 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus rates ZLDPF with a GF Score™ of 62/100 and a GF Value™ of $2,429.27 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 153 Biotechnology companies, Zealand Pharma AS ranks worse than 653594.12% on this metric.
Zealand Pharma AS's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Zealand Pharma AS's 5-Year Yield-on-Cost % or its related term are showing as below:
ZLDPF's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.65 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Zealand Pharma AS (OTCPK:ZLDPF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Zealand Pharma AS 5-Year Yield-on-Cost % Related Terms
ZLDPF vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Zealand Pharma AS's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's 5-Year Yield-on-Cost % falls into.
Zealand Pharma AS 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Zealand Pharma AS (ZLDPF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Zealand Pharma AS and its competitors. According to the industry distribution chart, Zealand Pharma AS ranks #999999 out of 153 companies in the Biotechnology industry.
Is Zealand Pharma AS's 5-Year Yield-on-Cost % too high?
Zealand Pharma AS's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Zealand Pharma AS ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Zealand Pharma AS in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.65, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPF) is currently considered Possible Value Trap. The stock's GF Value™ is $2,429.27, compared to a current price of $44.86 — trading 98.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Zealand Pharma AS's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?
Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued.
The current stock price of $44.86 is trading 98.2% below its estimated GF Value™ of $2,429.27.
GuruFocus considers Zealand Pharma AS to be Possible Value Trap.
Key valuation signals for ZLDPF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $2,429.27 vs. price of $44.86 (98.2% below fair value)
No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score
Get the complete analysis for ZLDPF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 